预处理强度对首次移植后复发患者第二次异基因造血细胞移植临床结局的影响
该回顾性研究分析了2478例因血液系统恶性肿瘤在首次异基因造血细胞移植(HCT1)后复发而接受第二次移植(HCT2)的患者。多因素分析显示,HCT2采用减低强度预处理(RIC)相比清髓性预处理(MAC)与更低的非复发死亡率(NRM)相关(HR 0.83,95%CI 0.72-0.97,p=0.018),但与总生存(OS)无显著相关(HR 0.91,95%CI 0.82-1.01,p=0.075)。在HCT1后发生广泛型慢性移植物抗宿主病(cGVHD)的患者中,RIC与更优的OS相关(HR 0.68,95%CI 0.49-0.93,p=0.02),且预处理强度与既往广泛型cGVHD史之间存在显著交互作用(交互p=0.01)。
要点
- HCT2采用RIC相比MAC与更低的NRM相关(HR 0.83,95%CI 0.72-0.97,p=0.018)。
- RIC与OS无显著相关(HR 0.91,95%CI 0.82-1.01,p=0.075)。
- HCT1后广泛型cGVHD患者中RIC与更优OS相关(HR 0.68,95%CI 0.49-0.93,p=0.02)。
核心结论
- 本研究表明HCT2采用RIC可降低NRM并改善OS,尤其在既往有广泛型cGVHD病史的患者中。
研究设计与样本
- 回顾性分析2478例因血液系统恶性肿瘤在HCT1后复发而接受HCT2的患者。
主要发现
- 多因素分析中,受者年龄较大、HCT1至HCT2间隔短、HCT1采用RIC、HCT-CI≥2、ECOG PS≥2与NRM风险增加相关。
- HCT2采用RIC相比MAC与更低的NRM相关(HR 0.83,95%CI 0.72-0.97,p=0.018)。
- HCT2采用RIC与OS无显著相关(HR 0.91,95%CI 0.82-1.01,p=0.075)。
- HCT1后广泛型cGVHD与HCT2预处理强度对NRM存在显著交互作用(交互p<0.001),RIC对NRM的获益见于HCT1后广泛型cGVHD患者,而不见于无cGVHD患者。
- HCT1后广泛型cGVHD患者中,HCT2采用RIC与更优OS相关(HR 0.68,95%CI 0.49-0.93,p=0.02),预处理强度与既往广泛型cGVHD史间交互作用显著(交互p=0.01)。
临床怎么用
- 作者认为,HCT2采用RIC可降低NRM并改善OS,尤其在既往有广泛型cGVHD病史的患者中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although second allogeneic hematopoietic cell transplantation HCT (HCT2) is a potentially curative treatment for patients relapsing after their first HCT (HCT1), it is associated with higher non-relapse mortality (NRM) compared with HCT1. Furthermore, while reduced-intensity conditioning (RIC) in HCT2 might decrease NRM, there is no consensus on which patients may benefit from RIC. We retrospectively analyzed 2478 patients who underwent HCT2 for relapse of hematologic malignancies after HCT1. In a multivariate analysis, older recipient age, short duration between HCT1 and HCT2, RIC in HCT1, HCT-CI ≥ 2, and ECOG PS ≥ 2 were associated with an increased risk of NRM. RIC in HCT2 was associated with better NRM compared to myeloablative conditioning (MAC) (hazard ratio [HR] 0.83, 95% confidence interval [CI]: 0.72-0.97; p = 0.018), but was not significantly associated with overall survival (OS) (HR 0.91, 95% CI: 0.82-1.01; p = 0.075). We observed a significant interaction for NRM between extensive cGVHD in HCT1 and the conditioning intensity of HCT2 (interaction p < 0.001), meaning that the benefit of RIC in HCT2 was seen in patients with extensive cGVHD in HCT1, but not in those without cGVHD. RIC in HCT2 was also associated with superior OS in patients with extensive cGVHD in HCT1 (HR 0.68, 95% CI: 0.49-0.93; p = 0.02), with significant interaction between the conditioning intensity and the prior history of extensive cGVHD (interaction p = 0.01). This study suggests that RIC in HCT2 reduces NRM for HCT2 and improves OS, especially in patients with a history of extensive cGVHD.
引用
- Yoshimura K, Nakasone H, Tamaki M, et al. Impact of Conditioning Intensity on Clinical Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Relapse After First Transplantation. Am J Hematol. 2025. PMID: 40407015. doi:10.1002/ajh.27709
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。